Financials
Financial year 2025
Lobelia Pharma from Brugge, company number BE0471133849, closed financial year 2025 with a result of € 274,161 after tax. For that financial year Lobelia Pharma recorded a gross margin of € 200,850 and equity of € 1.5 million. Compared with financial year 2024, the result moved from € 250,338 to € 274,161. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ 1.5 million
▲ 22% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 274,161
▲ 10% vs 2024
Profit after tax over the fiscal year.
€ 25,459
▲ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.5 million.
Debts at end 2025
€ 1.9 million
▲ 82% vs 2024
€ 120,639 is repaid this year. At this pace the long-term loan is gone in ≈ 16 years.
€ 1,913
▼ 64% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 63,039
▲ 70% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 57,007 | € 73,702 | € 79,128 | € 200,850 | ▲ 154% |
| Profit after taxes | € 92,150 | € 31,977 | € 250,338 | € 274,161 | ▲ 10% |
| Equity | € 958,187 | € 990,165 | € 1,240,502 | € 1,514,663 | ▲ 22% |
| Total debts | € 1,097,201 | € 1,152,901 | € 1,133,977 | € 2,031,471 | ▲ 79% |
| Cash | € 4,780 | € 13,899 | € 24,759 | € 25,459 | ▲ 3% |
| Land & buildings | - | - | - | € 927,917 | |
| Retained profit | € 939,587 | € 971,565 | € 1,221,902 | € 1,496,063 | ▲ 22% |
| Bank debt | € 257,142 | € 217,632 | € 1,063,021 | € 1,936,305 | ▲ 82% |
| Balance sheet total | € 2,055,388 | € 2,143,066 | € 2,374,480 | € 3,546,134 | ▲ 49% |
Key figures of Lobelia Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Lobelia Pharma?
What happened at Lobelia Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 274,161 (▲ 10% vs 2024). Source: NBB ↗
- Charlotte Delobel became a director. NBB
- New establishment in Jabbeke. KBO
- Start of the company according to the CBE. KBO
In short
From € 92,150 profit in 2022 to € 274,161 profit in 2025.
Paid € 115,944 in corporate taxes since 2022.
Best year ever: 2025, with € 274,161 profit.
Management
Behind Lobelia Pharma is Charlotte Delobel. It owns 99.2% of Pharma Link itself.
Directors
According to the 2025 annual accounts
since 2023
Establishments
Establishment units
Physical locations of this company
Koning Leopold III-laan 128
8200 Brugge
Intweg ZN box 3
8490 Jabbeke
Active since 13 April 2000
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0471.133.849
- VAT number
- BE 0471.133.849
- Registered office
- Koning Leopold III-laan 128, 8200 Brugge
- Names & denominations
- Lobelia Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 February 2000
- Peppol
- Active · Active since 24 Nov 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering